Double-Blind, Double Dummy, Randomized Comparison Study to Evaluate the Efficacy and Safety of Valdecoxib 10 mg Once Daily and Naproxen 500 mg Twice Daily in Treating the Signs and Symptoms of Osteoarthritis of the Knee
NCT00652808
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- Korean outpatients with symptomatic radiologic evidence of OA of the knee (diagnosed according to the modified American College Rheumatology criteria)
- Patient's Assessment of Arthritis Pain measurement of at least 40 mm on VAS
- Patients had not received any NSAIDs or analgesics within 2 days (within 4 days for subjects taking oxaprozin, piroxicam or full dose aspirin) prior to the Baseline Visit
- Diagnosis of inflammatory arthritis, gout, pseudogout, Paget's disease, or any chronic
pain syndrome that, in the Investigator's opinion, would interfere with the assessment
of the Index Knee
- Symptomatic anserine bursitis or acute joint trauma of the Index Knee
- Arthroscopy performed on the Index Knee within the past 12 months
- Complete loss of articular cartilage of the Index Knee
- Administration of oral, or intramuscular, intravenous, or soft tissue injections of
corticosterosteroids within 4 weeks prior to screening visit
- Administration of intra-articular injection of corticosteroids or hyaluronic acid
preparation in the Index Knee within 3 months or 6 months, respectively
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Anyang,
- Gwangju,
- Incheon,
- Pusan,
- Seoul,
- Seoul,
- Seoul,
- Seoul,
- Phoenix, Arizona
- Tucson, Arizona
- Long Beach, California
- Paramount, California
- Tustin, California
- Colorado Springs, Colorado
- Wheat Ridge, Colorado
- DeLand, Florida
- Naples, Florida
- Pembroke Pines, Florida
- Saint Petersburg, Florida
- Woodstock, Georgia
- Overland Park, Kansas
- New Orleans, Louisiana
- Baltimore, Maryland
- Flowood, Mississippi
- Chesterfield, Missouri
- Reno, Nevada
- Albuquerque, New Mexico
- Mason, Ohio
- Beaver, Pennsylvania
- Camp Hill, Pennsylvania
- Jenkintown, Pennsylvania
- Greensboro, South Carolina
- Johnson City, Tennessee
- Murfreesboro, Tennessee
- Nashville, Tennessee
- Austin, Texas
- San Antonio, Texas
- Seattle, Washington
- Birmingham, Alabama
- Buena Park, California
- Denver, Colorado
- Washington, District of Columbia
- Longwood, Florida
- Miami, Florida
- Zephyrhills, Florida
- Boise, Idaho
- Boise, Idaho
- Morton Grove, Illinois
- Wichita, Kansas
- Wichita, Kansas
- Wheaton, Maryland
- Springfield, Missouri
- Bozeman, Montana
- Trenton, New Jersey
- Binghamton, New York
- Brooklyn, New York
- New York, New York
- Cary, North Carolina
- Winston-Salem, North Carolina
- Bismarck, North Dakota
- Eugene, Oregon
- Portland, Oregon
- Duncansville, Pennsylvania
- Johnstown, Pennsylvania
- Warwick, Rhode Island
- Charleston, South Carolina
- New Tazewell, Tennessee
- San Antonio, Texas
- Arlington, Virginia
- Norfolk, Virginia
- Seattle, Washington
- DeLand, Florida
- South Miami, Florida
- Overland Park, Kansas
- Madisonville, Kentucky
- Chesterfield, Missouri
- Creve Coeur, Missouri
- St. Peters, Missouri
- New York, New York
- Cincinnati, Ohio
- Warwick, Rhode Island
- San Antonio, Texas
- Arlington, Virginia
- Clarksburg, West Virginia
- Seoul,
- Seoul,
- Seoul,
- Seoul,
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | Double-Blind, Double Dummy, Randomized Comparison Study to Evaluate the Efficacy and Safety of Valdecoxib 10 mg Once Daily and Naproxen 500 mg Twice Daily in Treating the Signs and Symptoms of Osteoarthritis of the Knee | |||
Official Title ICMJE | Double-Blind, Double Dummy, Randomized Comparison Study to Evaluate the Efficacy and Safety of Valdecoxib 10 mg QD and Naproxen 500 mg BID in Treating the Signs and Symptoms of Osteoarthritis of the Knee | |||
Brief Summary | This study was performed to demonstrate that treatment with valdecoxib 10 mg daily (QD) was at least as effective as with naproxen 500 mg twice daily (BID), a standard non-steroidal anti-inflammatory drug (NSAID), when taken for 6 weeks in Korean subjects with symptomatic osteoarthritis (OA) of the knee. Secondary objectives were to assess the overall safety and tolerability of valdecoxib 10 mg QD taken for 6 weeks in Korean subjects with symptomatic OA of the knee. | |||
Detailed Description | Not Provided | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 3 | |||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Triple (Participant, Investigator, Outcomes Assessor) Primary Purpose: Treatment | |||
Condition ICMJE |
| |||
Intervention ICMJE |
| |||
Study Arms ICMJE |
| |||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Completed | |||
Actual Enrollment ICMJE | 265 | |||
Original Actual Enrollment ICMJE | Same as current | |||
Actual Study Completion Date ICMJE | September 2004 | |||
Primary Completion Date | Not Provided | |||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | Korea, Republic of | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT00652808 | |||
Other Study ID Numbers ICMJE | A3471045 | |||
Has Data Monitoring Committee | No | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Director, Clinical Trial Disclosure Group, Pfizer, Inc. | |||
Study Sponsor ICMJE | Pfizer | |||
Collaborators ICMJE | Not Provided | |||
Investigators ICMJE |
| |||
PRS Account | Pfizer | |||
Verification Date | April 2008 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |